Delcath Systems Inc

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Its proprietary products include HEPZATO KIT (melphalan for Injection/Hepatic Delivery System), an FDA-approved combination drug and device product used for percutaneous hepatic perfusion (PHP) in the United States, and CHEMOSAT Hepatic Delivery System for Melphalan, a Class III medical device approved in Europe for use in PHP procedures. Both products are designed to deliver high-dose chemotherapy directly to the liver while filtering hepatic venous blood to minimize systemic exposure and associated side effects. HEPZATO KIT is currently approved for adult patients with metastatic uveal melanoma with unresectable hepatic metastases, and the company is expanding its clinical program into breast cancer and other indications with liver-dominant disease. Delcath operates through a growing network of active treatment centers and is debt-free with a substantial cash and investment position. Updated Aug 6, 2026